SD‐36 promotes growth inhibition and induces apoptosis via suppression of Mcl‐1 in glioma

Role of STAT3 signaling pathway in breast cancer

(2020) Jia-hui Ma et al.   Cell Communication and Signaling

Identification of a transient state during the acquisition of temozolomide resistance in glioblastoma

(2020) Marion Rabé et al.   Cell Death & Disease

miR‐126 reduces trastuzumab resistance by targeting PIK3R2 and regulating AKT/mTOR pathway in breast cancer cells

(2020) Rao Fu et al.   JOURNAL OF CELLULAR AND MOLECULAR MEDICINE

Proteolysis-targeting chimera (PROTAC) for targeted protein degradation and cancer therapy

(2020) Xin Li et al.   Journal of Hematology & Oncology

PROTAC Technology: Opportunities and Challenges

(2020) Hongying Gao et al.   ACS Medicinal Chemistry Letters

P2X7R promotes angiogenesis and tumour‐associated macrophage recruitment by regulating the NF‐κB signalling pathway in colorectal cancer cells

(2020) Chunhui Yang et al.   JOURNAL OF CELLULAR AND MOLECULAR MEDICINE

Acquired temozolomide resistance in MGMT-deficient glioblastoma cells is associated with regulation of DNA repair by DHC2

(2019) Guo-zhong Yi et al.   BRAIN

Degradation of proteins by PROTACs and other strategies

(2019) Yang Wang et al.   Acta Pharmaceutica Sinica B

Glioblastoma Multiforme: An Overview of Emerging Therapeutic Targets

(2019) Olivia G. Taylor et al.   Frontiers in Oncology

A Potent and Selective Small-Molecule Degrader of STAT3 Achieves Complete Tumor Regression In Vivo

(2019) Longchuan Bai et al.   CANCER CELL

Novel activators and small-molecule inhibitors of STAT3 in cancer

(2019) Lehe Yang et al.   CYTOKINE & GROWTH FACTOR REVIEWS

Role of Sonic hedgehog signaling in cell cycle, oxidative stress, and autophagy of temozolomide resistant glioblastoma

(2019) Jessica R. Honorato et al.   JOURNAL OF CELLULAR PHYSIOLOGY

Structure-Based Discovery of SD-36 as a Potent, Selective, and Efficacious PROTAC Degrader of STAT3 Protein

(2019) Haibin Zhou et al.   JOURNAL OF MEDICINAL CHEMISTRY

Inhibition of the PI3K but not the MEK/ERK pathway sensitizes human glioma cells to alkylating drugs

(2018) Bodo Haas et al.   Cancer Cell International

Targeting the IL-6/JAK/STAT3 signalling axis in cancer

(2018) Daniel E. Johnson et al.   Nature Reviews Clinical Oncology

PUMA amplifies necroptosis signaling by activating cytosolic DNA sensors

(2018) Dongshi Chen et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Hypoxia-Inducible Factor-1α Activity as a Switch for Glioblastoma Responsiveness to Temozolomide

(2018) Alessia Lo Dico et al.   Frontiers in Oncology

A novel enhancer regulates MGMT expression and promotes temozolomide resistance in glioblastoma

(2018) Xiaoyue Chen et al.   Nature Communications

FBW7 -Dependent Mcl-1 Degradation Mediates the Anticancer Effect of Hsp90 Inhibitors

(2017) Jingshan Tong et al.   MOLECULAR CANCER THERAPEUTICS

Strategies of temozolomide in future glioblastoma treatment

(2017) Chooi Yeng Lee   OncoTargets and Therapy

Metformin and temozolomide, a synergic option to overcome resistance in glioblastoma multiforme models

(2017) Silvia Valtorta et al.   Oncotarget

FBW7 mutations mediate resistance of colorectal cancer to targeted therapies by blocking Mcl-1 degradation

(2016) J Tong et al.   ONCOGENE

The symptom burden of primary brain tumors: evidence for a core set of tumor- and treatment-related symptoms

(2015) Terri S. Armstrong et al.   NEURO-ONCOLOGY

Multiple regulation pathways and pivotal biological functions of STAT3 in cancer

(2015) Jie Yuan et al.   Scientific Reports

Temozolomide resistance in glioblastoma cells occurs partly through epidermal growth factor receptor-mediated induction of connexin 43

(2014) J L Munoz et al.   Cell Death & Disease

Role of STAT3 in Cancer Metastasis and Translational Advances

(2013) Mohammad Zahid Kamran et al.   Biomed Research International

STAT3 Inhibition Overcomes Temozolomide Resistance in Glioblastoma by Downregulating MGMT Expression

(2012) Shinji Kohsaka et al.   MOLECULAR CANCER THERAPEUTICS